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Abstract
The CB1 cannabinoid receptor is the most abundant G-protein coupled receptor in the brain and a key regulator of
neuronal excitability. There is strong evidence that CB1 receptor on glutamatergic hippocampal neurons is beneficial to
alleviate epileptiform seizures in mouse and man. Therefore, we hypothesized that experimentally increased CB1 gene
dosage in principal neurons would have therapeutic effects in kainic acid (KA)-induced hippocampal pathogenesis. Here, we
show that virus-mediated conditional overexpression of CB1 receptor in pyramidal and mossy cells of the hippocampus is
neuroprotective and moderates convulsions in the acute KA seizure model in mice. We introduce a recombinant adeno-
associated virus (AAV) genome with a short stop element flanked by loxP sites, for highly efficient attenuation of transgene
expression on the transcriptional level. The presence of Cre-recombinase is strictly necessary for expression of reporter
proteins or CB1 receptor in vitro and in vivo. Transgenic CB1 receptor immunoreactivity is targeted to glutamatergic neurons
after stereotaxic delivery of AAV to the dorsal hippocampus of the driver mice NEX-cre. Increased CB1 receptor protein
levels in hippocampal lysates of AAV-treated Cre-mice is paralleled by enhanced cannabinoid-induced G-protein activation.
KA-induced seizure severity and mortality is reduced in CB1 receptor overexpressors compared with AAV-treated control
animals. Neuronal damage in the hippocampal CA3 field is specifically absent from AAV-treated Cre-transgenics, but evident
throughout cortical areas of both treatment groups. Our data provide further evidence for a role of increased CB1 signaling
in pyramidal hippocampal neurons as a safeguard against the adverse effects of excessive excitatory network activity.
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Introduction
Maintaining an optimal balance between excitatory and
inhibitory activity of central nervous system (CNS) neurons is
essential for proper physiological network activities, since either
excessive glutamatergic transmission or insufficient GABAergic
transmission can lead to excitotoxicity and epileptiform seizures in
rodents and man [1]. The endocannabinoid system represents a
molecular safeguard for efficient control of dangerous neuronal
overexcitation [2,3,4]. Endocannabinoids are produced on-
demand from endogenous lipid precursors, and act as retrograde
messengers that inhibit release of neurotransmitters by the
activation of presynaptic cannabinoid type 1 (CB1) receptors.
CB1 receptor activation has anticonvulsant and neuroprotective
effects in acute and chronic seizure models [5,6] and extracts of
the plant Cannabis sativa have been used as epilepsy medication
since thousands of years [4]. CB1 is expressed on both GABAergic
interneurons and glutamatergic principal neurons in the hippo-
campus [2,7,8,9,10], a region strongly implicated in the develop-
ment of epilepsy. The endocannabinoid system has been implied
as a therapeutical target in epilepsy [11] and as such, effective
treatment strategies utilizing CB1 receptor regulation require a
detailed understanding of CB1 receptor effects in neuronal
subtypes. To this end, the analysis of conditional mouse mutants
lacking CB1 receptors on different subtypes of neurons subjected
to the kainic acid (KA)-induced seizures revealed that CB1
receptors on hippocampal glutamatergic but not GABAergic
neurons are required for protection against excitotoxic seizures
[10]. In line with this pre-clinical data, specific down-regulation of
protein and mRNA of CB1 receptor on glutamatergic, but not on
GABAergic axon terminals had been reported in epileptic human
hippocampal tissue [12]. However, these conditional loss-of-
function studies have not yet been complemented by the
corresponding gain-of function approach entailing CB1 overex-
pression, preventing a comprehensive picture of CB1-mediated
control of overexcitation.
Here we examined the effects of increased CB1 gene dosage in
the hippocampus on the development of epileptiform seizures and
neuronal damage in the KA model. To that end, we have used
adeno-associated virus (AAV) vectors for the delivery of the CB1
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neurotropism, stereotaxic delivery of AAV has been used widely
for gene transfer to the rodent hippocampus in the context of
animal models of excitotoxic seizures [10,13]. However, conven-
tional AAV vectors transduce all types of hippocampal neurons
[14] that might result in confounding results. To avoid this
confounding factor, we restrict transgene expression exclusively to
principal neurons expressing Cre-recombinase, using an AAV-
expression cassette with a transcriptional stop cassette flanked by
loxP sites, preceding the transgene. In this study, we show that
somatic transfer of the CB1 gene to glutamatergic hippocampal
neurons is sufficient to provide protection against acute seizures
and neuronal damage.
Results
AAV-Stop-mediated transgene expression requires Cre-
induced recombination
The neurotropic AAV1/2 has previously been shown to
efficiently deliver genes to all neuronal subtypes of the rodent
hippocampus [10,14]. To restrict virus-mediated transduction to
glutamatergic hippocampal neurons our approach was to excise a
transcriptional termination element preceding the cDNA in the
AAV-expression cassette by providing Cre-recombinase in trans
(Fig. 1A). The packaging limit of AAV is 5.2 kb [15] and
accommodation of large transgenes requires minimizing the size of
cis elements in the expression cassette. To adhere to that concept,
we designed a transcriptional termination (‘Stop’) element
entailing two loxP sites (34 bp) flanking a herpes simplex virus
thymidin kinase polyadenylation site (70 bp) and a polyadenyla-
tion terminator (154 bp). The Stop cassette was cloned into our
latest generation AAV expression cassette [13] between the
cytomegalovirus enhancer/chicken beta actin (CBA) promoter
and the hrGFP (humanized renilla green fluorescent protein)
cDNA to obtain pAAV-Stop-GFP. We transfected human
embryonic kidney (HEK 293) cells with this reporter construct
to assess the efficacy of the Cre-induced AAV system in vitro.
Immunocytochemical analysis showed that the absence of Cre
recombinase prevented transcription of the reporter (Fig. 1E-G),
whereas co-transfection with a Cre plasmid caused efficient
activation of GFP expression (Fig. 1B–D).
For in vivo analysis, we injected either generic AAV-GFP or
conditional AAV-Stop-GFP to the hippocampus of adult (.2
months) wild-type mice (C57BL/6N) and Cre driver mice
expressing Cre specifically in glutamatergic forebrain neurons
under the control of regulatory sequences of the NEX gene (NEX-
cre). The NEX gene is active in pyramidal neurons and dentate
gyrus mossy cells, but not in interneurons, oligodendrocytes and
astrocytes, nor in granule cells of the dentate gyrus after P10 [16].
Mice were sacrificed at 4 weeks post-injection when AAV-mediated
transgene expression had peaked to remain at stable levels and
vector spread was determined by immunohistochemistry. GFP
immunoreactivity was observed throughout the dorsal hippocam-
pus of AAV-GFP-injected mice. As expected, transduction of all
types of neurons occurred in the hippocampal formation, CA1-3,
hilar region and the dentate gyrus (Fig. 1H–J). The abundant
reporter protein expression in processes of principal neurons
generally prevented visualization of transduced interneurons.
However, assessment of sections showing moderate GFP levels in
stratum radiatum and stratum lacunosum unmasked the presence
of GFP-immunoreactivity also in interneurons (Fig. 1H). In
contrast, no GFP immunoreactivity was detected after delivery of
AAV-Stop-GFP into wild-type mice (Fig. 1K–M), even after
prolonged exposure times (not shown), validating the effective
attenuation of transcription by the Stop cassette in vivo. In AAV-
Stop-GFP treated NEX-Cre mice (AAV-Glu-GFP), pyramidal
neurons showed robust GFP expression (Fig. 1N–P). As expected,
dentate granule cells were unlabeled indicating the lack of Cre
expression in these neurons at adult stages when AAV-delivery was
performed [16]. Co-localisation of GFP and Cre immunoreactivity
in the CA1 region of NEX-Cre mice suggests that activation of
transgene expression depends on the Cre-mediated recombination
of AAV genomes (Fig. 2). In summary, these findings demonstrate
that the presence of a small stop element confers tight spatio-
temporal control over transgene expression after AAV delivery to
Cre driver mouse lines.
Conditionally expressed CB1 receptor in hippocampal
pyramidal cells is functional
CB1 receptor is known to be expressed in distinct neuronal
subpopulations in the hippocampus [9,10,17] with very high levels
in GABAergic interneurons belonging mainly to the cholecysto-
kinin-positive and parvalbumin-negative type [9,18] and 20–30
times less CB1 receptor protein in glutamatergic pyramidal
terminals [17,19]. For a cell-type specific CB1 overexpression,
we replaced the reporter in pAAV-Stop-GFP with the coding
region of the HA-tagged rat CB1 receptor cDNA. The presence of
the HA-epitope tag facilitates immunological detection of the
transgene and allows specific assessment of ectopic versus
endogenous CB1 receptor protein. The AAV-Stop-CB1 vector
was administered to the hippocampus of adult NEX-Cre mice to
achieve conditional CB1 overexpression in hippocampal glutama-
tergic cells (AAV-Glu-CB1 mice). Wild-type littermates of NEX-
Cre mice that do not express Cre recombinase were also injected
with the AAV-Stop-CB1 vector and served as control group
(named as AAV-WT mice). Immunohistochemical detection of the
HA-tag revealed Cre-activated CB1 receptor expression in
hippocampal pyramidal neurons (Fig. 3A) in a similar pattern
compared to AAV-Stop-GFP-injected animals confirming the
integrity of the conditional AAV system. Co-localisation of ectopic
CB1 receptor and VGluT1 (vesicular glutamate transporter 1), a
marker for glutamatergic presynaptic sites, in the inner third of the
molecular layer of the dentate gyrus where the mossy cells are
synapsing on granule cell dendrites demonstrated presynaptic
location of ectopic CB1 protein (Fig. 3B–D). The subcellular
localization in glutamatergic cells of exogenous CB1 receptor
protein matches that of the endogenous receptor [10] and the
detection of HA-immunoreactivity in somata is likely to reflect
accumulated CB1 receptors destined for transport to axonal
terminals.
Furthermore, we examined CB1 protein levels in hippocampal
homogenates of AAV-Glu-CB1 and AAV-WT mice that were
sacrificed four weeks post-injection by western blot analysis
(Fig. 3E). CB1 receptor protein levels were significantly increased
in AAV-Glu-CB1 mice compared to controls following normal-
ization to tubulin (p,0.001; unpaired t test, two tailed). Increased
CB1 receptor levels may result in enhanced cannabinoid-induced
G protein activation and thus enhanced endocannabinoid
signaling. To address that, we performed HU-210-stimulated
[
35S]GTPcS binding with the same hippocampal homogenates of
AAV-Glu-CB1 and AAV-WT mice used for immunoblot analysis.
AAV-WT mice reached a maximum stimulation of 93.8%, over
baseline, while HU-210-induced G protein activation was
significantly increased in AAV-Glu-CB1 mice, reaching a
maximum of 224.4% (Fig. 3F; p=0.0001, unpaired t test, two-
tailed). Our quantitative biochemical analyses revealed an overall
CB1 receptor upregulation of 2.5-fold compared with controls.
However, this value might underestimates the true increase of CB1
Conditional Overexpression of CB1
PLoS ONE | www.plosone.org 2 December 2010 | Volume 5 | Issue 12 | e15707Figure 1. Cre recombinase-activated transgene expression. A, AAV expression cassette. Top, Silencing of transgene expression by
transcriptional termination cassette containing three polyadenylation sites flanked by loxP sites (triangles). Bottom, Cre recombinase-mediated
excision of the Stop cassette leading to transcription of the transgene. ITR, inverted terminal repeat; CBA, chicken-b-actin promoter; 3xpA, three
polyadenylation (pA) signals; GOI, gene of interest; WPRE, woodchuck hepatitis virus post-transcriptional regulatory element. B–G, HEK cells were co-
transfected with pAAV-Stop-GFP and pAAV-Cre (B–D) or pAAV-empty (E–G) and GFP immunofluorescence is strictly limited to Cre transfectants.
Transgene expression is tightly inhibited when pAAV-Stop-GFP is co-transfected with pAAV-empty. Blue: cell nucleus staining with DAPI, Green: GFP
immunostaining, Red: Cre recombinase immunostaining. Bar in G: 50 mm. H–P, Two months after stereotaxic vector delivery (AAV-GFP or AAV-Stop-
GFP) to the dorsal hippocampus of adult wild-type or NEX-Cre mice, GFP epifluorescence was assessed in brain sections. H–J, AAV-GFP efficiently
transduces all types of neurons of the hippocampal formation, in particular in CA1, CA2, CA3, the hilar region and the dentate gyrus. Note that
transduced interneurons (arrowheads in H) can be visualized in areas of low GFP abundance. GC, granule cell layer; Hil, hilar region; LMol, stratum
lacunosum-molecularis; Mol, stratum molecularis; Or, stratum oriens; Pyr, CA1/CA3 pyramidal cell layer; Rad, stratum radiatum. K–M, After AAV-Stop-
GFP injection, GFP expression was not detectable in wild-type mice. N–P, In NEX-Cre mice, neurons of the pyramidal cell layer express the reporter
gene, while granule cells of the dentate gyrus are spared. Note that in this mouse line, Cre recombinase is not expressed in the adult dentate gyrus
(see Goebbels et al., 2006). Bar in M: 250 mm.
doi:10.1371/journal.pone.0015707.g001
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moderate expression levels of endogenous CB1 protein in this
neuronal subtype.
Taken together, we demonstrated ectopic CB1 receptor to be
robustly expressed cell-type specifically in hippocampal pyramidal
neurons, to be located at presynaptic sites and to be coupled to G
Figure 2. Recombination of AAV genomes is restricted to Cre-expressing neurons in vivo. AAV-Stop-GFP was injected to the
hippocampus of NEX-Cre transgenic mice and GFP expression visualized in brain sections two months later. Transduced CA1 pyramidal neurons
express GFP (A) and Cre recombinase (B). As expected, the merge picture (C) shows segregated subcellular expression domains of the cytosolic GFP
and the nuclear Cre. Bar: 25 mm.
doi:10.1371/journal.pone.0015707.g002
Figure 3. Transgenic HA-tagged CB1 receptor is expressed in hippocampal pyramidal neurons. AAV-Stop-CB1 was injected bilaterally to
the hippocampus of NEX-Cre transgenic (AAV-Glu-CB1) mice and their respective wild-type (AAV-WT) littermates. A, Cre-activated CB1 expression
occurred in pyramidal neurons and appeared in a similar pattern compared to AAV-Stop-GFP confirming the integrity of the system. GC, granule cell
layer; Hil, hilar region of dentate gyrus; LMol, stratum lacunosum-molecularis; Mol, stratum molecularis; Or, stratum oriens; Pyr, CA1/CA3 pyramidal
cell layer; Rad, stratum radiatum. Bar: 250 mm. B-D, Higher magnification micrographs of dentate granule cells shown in A. Immunohistochemistry for
the HA-tag reveals co-expression of CB1 and VGluT1 in the inner molecular layer of the dentate gyrus, validating the presynaptic localization of
transgenic CB1 receptor. Bar in D: 25 mm. E, Western blot analysis of hippocampal homogenates of AAV-Glu-CB1 (n=3) and AAV-WT (n=3) mice.
AAV-Glu-CB1 mice express significantly increased levels of CB1 receptor protein. Data are normalized for a-tubulin (p,0.001; unpaired t test analysis,
two-tailed). F, Stimulation of [
35S]GTPcS binding in hippocampal homogenates of AAV-Glu-CB1 mice (n=6) and AAV-WT littermates (n=3) was
determined by various concentrations of the CB1 agonist HU-210. Basal binding was measured in absence of HU-210 and defined as 0% in each
experiment. Data are presented as percentage stimulation above basal [
35S]GTPcS binding and are the means 6 SEM, all performed in duplicates. The
non-linear regression curve illustrates that overexpression of the CB1 receptor in hippocampal pyramidal neurons resulted in significantly enhanced
cannabinoids-induced G-protein activation and thus increased cannabinoid signaling. EC50=3.2660.08 nM (AAV-Glu-CB1), 2.9760.13 nM (AAV-WT);
Emax =224.467.39 (AAV-Glu-CB1), 93.7764.99 (AAV-WT). Unpaired t test analysis, two-tailed: p,0.0001.
doi:10.1371/journal.pone.0015707.g003
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istics of endogenous CB1 protein.
Increased CB1 receptor gene dosage in hippocampal
glutamatergic neurons confers protection against
epileptiform seizures
CB1 activation on glutamatergic neurons has been shown to
play an essential role in the protection against excitotoxic seizures
[5,6,10,20]. This provided the rationale to investigate the
therapeutic potential of CB1 receptor overexpression in the
context of the pathogenic consequences of experimentally induced
overexcitation of glutamatergic circuits in the hippocampus.
Kainic acid (KA) was injected (30 mg/kg, i.p.) to AAV-Glu-CB1
and AAV-WT mice to induce robust activation of excitatory
pathways resulting in acute epileptiform seizures. At every time
point of scoring seizure severity was moderated in AAV-Glu-CB1
mice compared to wild-type controls (Fig. 4A) without reaching
statistical significance (p=0.065, Mann Whitney test, two-tailed).
However, the average behavioral score over a period of 120 min is
significantly decreased in AAV-Glu-CB1 mice (Fig. 4B,
p=0.0007, Mann Whitney test, two-tailed). Severe KA-induced
motor seizures can be fatal. Kaplan-Meier survival analysis
demonstrated a significant difference between both genotypes in
the course of the KA treatment (Fig. 4C, p=0.0494, log rank test).
At 60 min after KA-injection, 93% of AAV-Glu-CB1 mice
(n=15) versus 72% of control animals (n=11) were alive
(Fig. 4C). 180 min after the start of the experiment, 53% of
AAV-Glu-CB1 mice but only 18% of AAV-WT mice had
survived. No animals died at later stages.
Importantly, we have shown previously, that expression of Cre
recombinase in glutamatergic neurons of the forebrain per se does
not alter susceptibility to KA-induced seizures [5]. These results
show that CB1 overexpression in glutamatergic hippocampal
neurons ameliorates the severity of acute epileptiform seizures
indicating an essential role of hippocampal pyramidal neurons and
mossy cells in CB1-dependent on-demand protection against
excessive excitatory activity.
CB1 receptor overexpression and excitotoxicity
Systemic KA treatment leads to neuronal degeneration
especially in CA3 pyramidal neurons of the hippocampus [1].
Five days after kainic acid injections, mice were sacrificed and
brain sections were stained with Fluoro-Jade C (FJC), a green
fluorescent dye specific for labeling degenerating neurons [21].
Robust neuronal cell death was evident in subcortical areas of both
AAV-Glu-CB1 (n=6) and AAV-WT (n=5) mice; however the
hippocampus of AAV-Glu-CB1 was virtually spared. Representa-
tive pictures of FJC-labeled cells in the CA3 area (Fig. 5B,D) and
in the neocortex (Fig. 5A,C) of AAV-Glu-CB1 and AAV-WT mice
are shown. Fluoro-Jade labeling of degenerating neurons is known
to be preserved even 2 weeks after KA injection [22], excluding
the possibility that CA3 pyramidal cells of AAV-Glu-CB1 mice
might have already died 5 days after KA injection and hence did
not stain. Moreover, FJC-positive cell counts in the cortex,
revealed a similar extent of neurodegeneration in both groups
(Fig. 5E), but neuronal damage was almost absent in the CA3 area
of AAV-Glu-CB1 mice (Fig. 5F, p=0.012, unpaired t test analysis,
two-tailed). This finding demonstrates that genetically increased
levels of CB1 receptor in glutamatergic cells of the hippocampus is
sufficient to provide protection from excitotoxic cell death after
prolonged motor seizures.
Discussion
Our data demonstrate that incorporation of the highly versatile
Cre-loxP system [23] into the AAV platform allows tight control
over expression of almost any gene in subsets of neurons under
very precise spatio-temporal control in vivo. The Cre-activated
AAV system affords a broad application spectrum comprising (1)
analysis of the Cre expression pattern of newly generated cell-type
specific Cre driver mice; (2) intense labelling of neurons to trace
long-range axon projections to reveal connectivity of specific
regions within the brain; (3) manipulation of neurons by
expression of light-activated ion channels to selectively induce
network activity [24,25,26] and (4) overexpression of the gene of
interest in a neuronal subpopulation. Cre-activated transgene
expression in a neuronal subpopulation is determined by the
transgenic mouse line driving Cre recombinase under a cell-type
specific promoter. To achieve an overexpression of the gene of
interest, Cre expression must resemble the expression pattern of
the gene of interest in the particular brain region. Therefore, the
choice of the Cre driver line requires serious consideration. In our
proof-of-principle experiments, analysis of Cre-mediated recom-
bination revealed reporter gene expression in the NEX-Cre line in
pyramidal CA1, CA2 and CA3, and hilar mossy cells while
Figure 4. Behavioural effects of elevated CB1 receptor levels in hippocampal pyramidal neurons and mossy cells. Seizures were
induced in AAV-Glu-CB1 mice (n=15) and AAV-WT controls (n=11) by i.p. injection of kainic acid (30 mg/kg). A, Seizure severity was reduced in AAV-
Glu-CB1 mice at every time point of scoring compared to AAV-WT controls without reaching significance (p=0.065, Mann Whitney test, two-tailed).
B, The average behavioral score over a period of 120 min is significantly decreased in AAV-Glu-CB1 mice (p=0.0007, Mann Whitney test, two-tailed)
indicating improved protection against KA-induced seizures. C, Kaplan–Meier survival curves of AAV-Glu-CB1 and AAV-WT mice during KA treatment
are significantly different between both genotypes (p=0.0494, log rank test). The survival rate at 180 min after KA injection was 53% of AAV-Glu-CB1
vs. 18% of AAV-WT mice.
doi:10.1371/journal.pone.0015707.g004
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expression in the hippocampus of NEX-Cre mice resembles
endogenous CB1 receptor expression in hippocampal glutamater-
gic neurons [10].
In the present study, we demonstrate that increased CB1
receptor levels in hippocampal glutamatergic neurons protect
against excitotoxic seizures. This finding is in agreement with
previous conditional knock-out studies that CB1 activation on
glutamatergic terminals, especially of mossy cells projecting to
dentate granule cells, plays an essential role in the protection
against excitotoxic seizures [5,10], while genetic CB1 ablation
from GABAergic interneurons had no effect on seizure severity
[10]. Excessive excitatory neurotransmission causes an increase in
Ca
2+ influx leading to neuronal degeneration, a harmful process
known as excitotoxicity [1]. The dispersal of excessive excitatory
neurotransmission finally results in behavioral symptoms, such as
paroxysmal seizures. It is thought that this procedure participates
in the progress of various forms of epilepsy. The endocannabinoid
system can dampen glutamatergic transmission via CB1 receptors
[2,3,19,27] and therefore represents a control system to limit the
danger of excessive excitatory activity. Our genetic data are
supported by the findings of several pharmacological studies. Anti-
convulsive effects in acute seizure models were demonstrated after
increasing endocannabinoid signaling through systemic adminis-
tration of CB1 receptor agonists [28], or endocannabinoid
degradation inhibitors [5,29,30], while application of CB1
receptor antagonist SR141716A can block the anticonvulsant
effect of cannabinoids [5,28]. Moreover, seizure activity is
accompanied by increased synthesis of the endocannabinoids
anandamide [5] and 2-AG [6,31].
In the hippocampus of patients with temporal lobe epilepsy CB1
receptor expression and the fraction of glutamatergic axon
terminals equipped with CB1 are downregulated [12]. As a
consequence, negative feedback control at excitatory synapses is
impaired in epileptic patients. Interestingly, recent studies
demonstrated that CB1 receptor expression undergoes a long-
term redistribution in the hippocampus following epileptogenesis
in the pilocarpine model of acquired epilepsy [6,20]. Falenski et al.
suggested that the redistribution might serve as a compensatory
effect comprising an upregulation of CB1 receptor in glutamater-
Figure 5. Increased CB1 receptor levels prevent degeneration of CA3 pyramidal neurons. Assessment of neurodegeneration by Fluoro-
Jade C (FJC) staining 5 days after exposure to KA. A–D, Representative images show FJC staining in the cortex and hippocampus of AAV-WT mice
(A, B) and AAV-Glu-CB1 mice (C, D). Insets show magnifications of FJC-labeled neurons in the cortex (A, C) and the CA3 area (B, D). CPu, caudate
putamen; Ctx, cortex; DG, dentate gyrus; LV, lateral ventricle. Bar in D: 250 mm. E, Quantification of FJC-labeled neurons demonstrated comparable
levels of neurodegeneration in the cortex in both groups. F, In contrast, degeneration of CA3 pyramidal neurons was blocked in AAV-Glu-CB1 but not
in AAV-WT mice (p,0.05, unpaired t test analysis, two-tailed).
doi:10.1371/journal.pone.0015707.g005
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results support the hypothesis that CB1 receptor in glutamatergic
hippocampal neurons is essential to provide endogenous protec-
tion against KA-induced seizures. However, recent reports on an
anti-convulsive role of CB1 receptor signaling in GABAergic
neurons in different seizure models suggest that a potential
therapeutic efficacy of cannabinoids might depend on the type of
epilepsy [32,33].
We demonstrated that elevated CB1 receptor levels safeguard
from neuronal cell death caused by excessive excitatory neuro-
transmission. This result is consistent with our previous studies
[5,10], showing that genetic deletion of CB1 receptor from
principal forebrain neurons results in higher levels of neuronal
degeneration in the hippocampus following KA treatment.
In conclusion, we provided strong evidence for the protective
role of CB1 receptor on hippocampal glutamatergic terminals as a
molecular stout guard in controlling excessive network activity [4].
Thus, CB1 receptor expression on hippocampal glutamatergic
neurons may represent a target for novel agents to restrain
excitotoxic events and to treat neurodegenerative diseases.
Materials and Methods
Ethics statement
Experiments were approved by the local animal care committee
(Landesuntersuchungsamt Koblenz, permit numbers 23177-07/
051-47V1 and 23177/G10-1-037).
DNA constructs
All constructs used in this study were based on a AAV
expression cassette containing the 1.1 kb CMV immediate early
enhancer/chicken b-actin hybrid promoter (CBA), the humanized
renilla GFP (hrGFP) cDNA, the woodchuck hepatitis virus post-
transcriptional regulatory element (WPRE), and the bovine growth
hormone polyadenylation sequence (bGHpA) flanked by AAV2
inverted terminal repeats (pAAV-GFP). The 340 bp transcrip-
tional Stop cassette was designed to entail a herpes simplex virus
thymidin kinase pA signal and a pA terminator from pGL3
(Promega, Madison, USA) flanked by loxP sites, and was
synthesised by a commercial provider (Epochbiolabs, Missouri
City, USA). The Stop cassette was then transferred into the
BamHI-site downstream of CBA in pAAV-GFP to obtain pAAV-
CBA-Stop-GFP-WPRE-bGHpA (pAAV-Stop-GFP). The rat CB1
open reading frame, fused downstream the coding region of the
hemagglutinin (HA)-tag, replaced GFP in pAAV-Stop-GFP to
obtain pAAV-CBA-Stop-CB1-WPRE-bGHpA (pAAV-Stop-
CB1). In addition, the pAAV backbone with no cDNA (pAAV-
empty) or with the sequence encoding Cre-recombinase fused to
the HA-tag and a nuclear localization signal (pAAV-Cre) were
used for in vitro experiments.
AAV vector administration
Production of pseudotyped AAV1/2 chimeric vectors and
determination of genomic titres using the ABI 7500 real time PCR
cycler (Applied Biosystems) were performed as described [13,34].
Adult male NEX-Cre mice [16], and wild-type littermates (26–
30 g) were anaesthetised as described [35], and 1 ml of either
AAV-GFP, AAV-Stop-GFP or AAV-Stop-CB1 (7610
10 viral
genomes/ml) was injected bilaterally into the hippocampus
(+2.0 mm AP, 62.0 mm ML, 22.0 mm DV from bregma).
Vector delivery was performed at a rate of 150 nl/min using a
microprocessor controlled mini-pump (World Precision Instru-
ments, Sarasota, FA, USA) with 34xG beveled needles (World
Precision Instruments) in a stereotaxic frame (Kopf Instruments,
Tujunga, CA, USA).
Immunohistochemistry
Brain sections were Immunostained as described [35]. Briefly,
free-floating brain sections (40 mm) were incubated overnight with
the following primary antibodies (1:1000 in immunobuffer): rabbit
anti-hrGFP (Stratagene, LaJolla, CA), rabbit anti-Cre (Covance,
Richmond, CA), rabbit anti-HA (Santa Cruz Biotechnology,
Santa Cruz, CA), and guinea pig anti-VGlut1 (Chemicon,
Temecula, CA). Sections were washed and then incubated for
1 h with the appropriate Alexa488 or Alexa546-conjugated goat
IgG (1:1000, Invitrogen, Eugene, OR). Before the third wash in
PBS, sections were counterstained with the nuclear dye 49,6-
diamidino-2-phenylindole (DAPI) for 5 min. Sections were then
transferred onto glass slides and coverslipped with Moviol
mounting medium and fluorescence was visualized using a
Olympus SZ61 Stereo microscope (Olympus Corporation, Tokyo,
Japan) or a laser scanning confocal microscope (Zeiss, Axiovert
LSM 710).
Induction of acute excitotoxic seizures
Kainic acid (Ascent scientific, Bristol, UK) was dissolved in
0.9% saline and administered (30 mg/kg; i.p.) in a volume of
10 ml/kg body weight to induce epileptiform seizures. A trained
observer blind to the genotype of the mice monitored the severity
of seizures for 2 hrs and scored every 15 min according to the
following scale [10]: 0 - no response; 1 - immobility and staring; 2 -
forelimb and/or tail extension, rigid posture; 3 - repetitive
movements, head bobbing; 4 - rearing and falling; 5 - continuous
rearing and falling: 6 - severe clonic-tonic seizures; 7 - death.
Fluoro-Jade staining
For detection and quantification of neuronal degeneration
evoked by kainic acid injection, Fluoro-Jade C (Millipore,
Schwalbach, Germany) staining was performed as described
previously [36]. Sections were collected every 120 mm for analysis
of neuronal degeneration of hippocampal neurons in each mouse
(10 sections per animal). Fluoro-Jade staining was visualized under
a FITC filter and quantified by two independent observers
unaware of the genotype.
Western Blot
Hippocampi of AAV-Glu-CB1 mice and AAV-WT mice were
isolated and homogenized in 1 ml of ice-cold membrane buffer
(50 mM Tris-HCl, pH 7.4, 3 mM MgCl2, 0.2 mM EGTA,
Complete protease inhibitor; Roche, Basel, Switzerland). Follow-
ing determination of protein content, aliquots were mixed with an
equal volume of 26 Laemmli reducing sample buffer. 10 mgo f
total protein were resolved by 12% SDS-PAGE and electro-
blotted onto nitrocellulose membrane. After blocking in 5% non-
fat dry milk, the membrane was incubated with primary antibodies
(aCB1 (Frontier Sciences, Hokkaido, Japan) or rabbit aHA (at
1:1000) at 4uC overnight. a-tubulin (Sigma-Aldrich, St. Louis,
MO) was used as loading control. Secondary antibodies were
horseradish peroxidase-conjugated anti-rabbit or anti-mouse IgG
(Dianova, Hamburg, Germany). Western blot analysis was
performed using a chemiluminescence system (Luminol). Detec-
tion was made by autoradiography.
Agonist-stimulated [
35S]GTPcS Binding
Briefly, hippocampus homogenates (10 mg) of AAV-Glu-CB1
mice and AAV-WT mice, in which AAV-mediated CB1
Conditional Overexpression of CB1
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the binding assay as described [37].
Data analysis
Data are presented as means 6 SEM and were analyzed using
unpaired, two-tailed t-test for normally distributed variables to
evaluate statistical significance with p,0.05 as level of statistical
significance. Non-normally distributed seizure scores were ana-
lyzed using the two-sided Mann-Whitney U-test with p,0.05 as
level of statistical significance. Western blot quantification was
performed using NIH ImageJ (Image Processing and Analysis in
Java). For agonist-stimulated [
35S]GTPcS binding, data were
analyzed with GraphPad Prism 4.0 software using nonlinear
regression and sigmoidal curve fitting to obtain potency (EC50) and
efficacy (Emax) values. Basal binding was measured in the absence
of cannabinoid receptor agonists and defined as 0% in each
experiment. All data are expressed as percentage stimulation
above basal [
35S]GTPcS binding. The Kaplan-Meier method was
used to evaluate survival, followed by the log rank test to identify
significant differences. Graphs and statistics were generated by
GraphPad Prism 4.0 (GraphPad Software, La Jolla, CA).
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